Stock CMMB CHEMOMAB THERAPEUTICS LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Chemomab Therapeutics Ltd.

Equities

CMMB

US16385C1045

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.67 USD 0.00% Intraday chart for Chemomab Therapeutics Ltd. +13.56% +31.37%
Apr. 10 Transcript : Chemomab Therapeutics Ltd. - Special Call
Mar. 07 Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI

Evolution of the average Target Price on Chemomab Therapeutics Ltd.

Price target over the last 5 years

History of analyst recommendation changes

3e4e740ea.aFIYQWSh-RR-T_OX5LIJItIjMlaOlNS4SpgLhG7JzWw.DhhANSjirEMWFp7wvsg8UIRVSgLk4Jv_eKk4wiOjjF5fOlIQFMmSYRpitg~4baee471fe2d5012ccd0be7ce61419af

Analyst Recommendations on Chemomab Therapeutics Ltd.

Roth MKM Starts Chemomab Therapeutics at Buy, $7 Price Target MT
Oppenheimer Downgrades Chemomab Therapeutics to Perform From Outperform, Removes $7 Price Target MT
Oppenheimer Adjusts Chemomab Therapeutics Price Target to $7 From $12, Maintains Outperform Rating MT
Oppenheimer Adjusts Chemomab Therapeutics' Price Target to $20 From $30, Maintains Outperform Rating MT
Aegis Capital Initiates Chemomab Therapeutics at Buy Rating With $30 Price Target MT
Oppenheimer Adjusts Chemomab Therapeutics PT to $30 From $42, Maintains Outperform Rating MT
CHEMOMAB THERAPEUTICS : Cantor Fitzgerald Initiates Coverage on Chemomab Therapeutics With Overweight Rating, $45 Price Target MT
CHEMOMAB THERAPEUTICS : Oppenheimer Initiates Coverage on Chemomab Therapeutics With Outperform Rating, $42 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.67 USD
Average target price
7 USD
Spread / Average Target
+944.78%
High Price Target
7 USD
Spread / Highest target
+944.78%
Low Price Target
7 USD
Spread / Lowest Target
+944.78%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Chemomab Therapeutics Ltd.

Roth MKM
Oppenheimer
Aegis Capital
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. CMMB Stock
  4. Consensus Chemomab Therapeutics Ltd.